Dec 07, 2021 9:00am EST JanOne Inc. Acquires an Option for the Rights to a Worldwide, Exclusive License for a Novel Strategy for Treating Methamphetamine Use Disorder
Sep 28, 2021 4:05pm EDT JanOne Encouraged By Recent FDA Communications Regarding Phase 2B Clinical Trial Design of Lead Drug Candidate JAN101
Jul 22, 2021 9:45am EDT JanOne Selects CPC Clinical Research as Trial Manager for Phase 2b Study of JAN101 for Peripheral Artery Disease Patients
Jun 23, 2021 10:10am EDT JanOne Readies Clinical Supply of Lead Product Candidate JAN101 for Distribution to Phase 2b Trial Sites
Jun 22, 2021 9:46am EDT JanOne Selects Regulatory Partner for Phase 2b Trial as Investigational Plan is Prepared for FDA Filing
Jun 15, 2021 10:15am EDT JanOne Appoints Internationally Renowned Expert on Addiction Nicholas Goeders, Ph.D. to Scientific Advisory Board
Jun 10, 2021 10:15am EDT JanOne Engages DC Consulting LLC for Government and Private Sector Initiatives
Jun 08, 2021 9:45am EDT JanOne Advances Toward Initiation of Phase 2b Peripheral Artery Disease (PAD) Trial for Lead Product Candidate JAN101
Feb 25, 2021 9:29am EST JanOne Announces Definitive Agreement to Sell its Legacy Recycling Business for $25 Million
